TY - JOUR
T1 - Animal models for antiphospholipid syndrome in pregnancy
AU - Ziporen, L.
AU - Blank, M.
AU - Shoenfeld, Y.
N1 - Funding Information:
This work was done as part of PhD thesis of L. Ziporen, MSc and was supported by grant given by Freda and Leon Schaller for research in autoimmunity.
PY - 1997
Y1 - 1997
N2 - Experimental models for antiphospholipid syndrome (APS) have been established recently in lupus-prone mice and induced in naive mice. The induction of APS is performed by passive infusion or active immunization of antiphospholipid antibodies (aPL) or the cofactor β2GP-1. High levels of diverse aPL develop in the animals in conjunction with clinical manifestations similar to the human disease, entailing low fecundity rate, fetal resorptions, thrombocytopenia, prolonged activated partial thromboplastin time, and neurological and behavioral impairments. The pathogenicity of aPL was confirmed in an in vivo thrombosis model. Immunomodulation of APS manifestations and treatment regimens in the experimental models are discussed.
AB - Experimental models for antiphospholipid syndrome (APS) have been established recently in lupus-prone mice and induced in naive mice. The induction of APS is performed by passive infusion or active immunization of antiphospholipid antibodies (aPL) or the cofactor β2GP-1. High levels of diverse aPL develop in the animals in conjunction with clinical manifestations similar to the human disease, entailing low fecundity rate, fetal resorptions, thrombocytopenia, prolonged activated partial thromboplastin time, and neurological and behavioral impairments. The pathogenicity of aPL was confirmed in an in vivo thrombosis model. Immunomodulation of APS manifestations and treatment regimens in the experimental models are discussed.
UR - http://www.scopus.com/inward/record.url?scp=0031046399&partnerID=8YFLogxK
U2 - 10.1016/S0889-857X(05)70317-3
DO - 10.1016/S0889-857X(05)70317-3
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:0031046399
SN - 0889-857X
VL - 23
SP - 99
EP - 117
JO - Rheumatic Disease Clinics of North America
JF - Rheumatic Disease Clinics of North America
IS - 1
ER -